INTRODUCTION AND OBJECTIVES: Cystic renal cell carcinomas (RCC) are suggested to be clinically indolent. As such, a distinct pathologic staging category for these lesions was recently proposed. While not without merit, these recommendations fail to account for limitations in the ability of modern imaging to differentiate cystic RCC from more biologically aggressive mimics. We evaluated the frequency of high grade kidney cancer in the highly selected cohort of surgically resected renal masses having cystic appearance on pre-operative radiographic imaging.
METHODS: A prospectively maintained institutional database was queried for clinically cystic renal masses that underwent surgery from January 2000 -June 2016 (n¼2,729 kidney surgeries). Patient and tumor characteristics including age at surgery, smoking history, Charlson comorbidity index (CCI), gender, race, BMI, surgery date, laterality, Bosniak classification, histology, grade, size, and nearness to the collecting system were tabulated. Associations between tumor grade and patient/tumor characteristics were evaluated using generalized estimating equations.
RESULTS: Eighty-nine patients (n¼101 cystic lesions) met strict inclusion criteria; the majority (77%) were older than 50 years of age and the mean Charlson comorbidity index was 1.15 (SD1.48) (Table 1) . Of the 101 clinically cystic renal masses, 23% were confirmed pathologically as high grade RCC while 77% were low grade RCC (n¼56) or benign (n¼22). CCI was associated with high grade surgical pathology (OR 1.37, 95% CI 1.05-1.79, p ¼ 0.02). There was no association between tumor grade and the remainder of the patient/ tumor characteristics analyzed.
CONCLUSIONS: Recently proposed changes to the kidney cancer staging system define a tumor's cystic nature based on pathologic examination. Proceeding with surgery for a radiographically "cystic" renal mass was a rare event in our cohort; however, among those that went onto surgery, nearly a quarter harbored high grade pathology. Before making changes to the clinical RCC staging system, a better understanding of the limitations inherent to radiographic determination of low malignant potential, cystic renal masses is necessary.
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PD52-09 THROMBOEMBOLIC EVENTS DURING TREATMENT FOR RENAL CELL CARCINOMA: MUST WE PREVENT?
INTRODUCTION AND OBJECTIVES: Renal mass detection has been on a steady incline over the past decade and subsequently, surgery for solid renal masses has also increased. 900,000 Americans are diagnosed with a VTE each year with the average cost being $56,000 to treat each incident. VTE is the number two cause of death behind the primary malignancy itself. As quality indicators and outcomes are more frequently being linked with reimbursement, venous thromboembolism (VTE) prevention has gained increased attention. Increasing the number of surgeries will also increase the incidence of VTE. The purpose of this study is to identify the incidence of VTE among renal cell carcinoma patients that have undergone definitive surgical therapy and to see if pharmacological prophylaxis following surgery is warranted.
METHODS: Over a fourteen year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) , all patients who had surgery for renal cell carcinoma were examined. A total of 900 patients had either open, laparoscopic or robotic surgery. This included partial, radical and cytoreductive nephrectomies. All VTE incidents that had occurred up until 2015 were documented. Patient demographics and comorbidities were analyzed for risk factors for VTE. All VTE incidents were documented in adjunct with known risk factors for each patient.
RESULTS: Of the 900 patients that were evaluated, 10 were documented to have VTE, making the incidence 1.1%. 40% of these patients had a prior history of VTE. 20% of the patients with a VTE had metastatic disease at time of surgery. 90% of patients were obese with a mean BMI of 32.3. 50% of patients with postoperative VTE had tobacco use. 100% of patients with documented VTE had at least 1 risk factor for VTE while 80% of patients had greater than 2 risk factors.
CONCLUSIONS: VTE incident following renal cell carcinoma surgery was found to be 1.1%. All patients had at least one risk factor in addition to surgery. The rate of significant postoperative bleeding following surgical therapy for renal cell carcinoma requiring transfusion is noted to be 3-6%. Risks of postoperative bleeding and other complications outweigh the benefit pharmacological VTE may have with such a low incidence of VTE. Early ambulation and mechanical VTE prophylaxis are warranted following surgery. Although VTE was a rare event, those with multiple risk factors may warrant special consideration and more aggressive VTE prophylaxis following surgery. . Until now, no reliable markers are found to predict the age-related tumor risks in VHL patiens. The present study has evaluated the influence of peripheral leukocyte telomere length on age-related tumor risks in a large group of VHL patients.
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METHODS: Genomic DNA was extracted from peripheral blood of 187 VHL patients. Tumor onset age was defined as the age when any symptom or imaging sign of the tumor first occurred. Age-related risks of the five tumors were evaluated using Kaplan-Meier plot and Cox regression model. Relative telomere length(RTL) was measured with qRT-PCR method.
RESULTS: The main death-causing tumor CNS hemangioblastoma occurred in 53.5%(100/187) VHL patients in our study, and the mean onset age was 30.2AE11.3 years old. In the shorter RTL group(RTL<0.44), the first tumor onset age was 7.7 years earlier than the longer one(25.2AE8.6y vs 32.9AE12.3y, p<0.001). The shorter RTL group displayed a statistically higher age-related risks than the longer RTL group for CNS(HR1.99, p¼0.001), RCC(2.02, p¼0.0030), PCT(2.11, p<0.001) and Pheo(3.13, p¼0.005) .
CONCLUSIONS: We for the first time propose that peripheral leukocyte telomere length may be associated with risks of VHL-related tumors, which may be helpful for establishing personalized surveillance plan for VHL patients and for further understanding the pathogenesis of VHL disease. . Models for localized disease, especially those that incorporate pathologic features, are highly accurate, while models for metastatic disease have inferior predictive ability. Thus, we investigated the gene expression profile in metastatic RCC to improve prognostication and provide a rationale for future biologic studies.
METHODS: A custom Nanostring panel was used to evaluate 124 candidate genes on specimens from 111 patients with resected primary and matched metastatic clear cell RCC between 1990 and 2005., No patient received systemic therapy prior to metastasectomy. After initial candidate genes were identified, a multivariable gene expression model was built using the lasso method and a scoring algorithm to predict likelihood of death was developed using the coefficients. Multivariable Cox regression used to determine if the scoring algorithm was predictive after adjusting for our previously published algorithm for metastatic RCC.
